Leading Independent Proxy Advisory Firm ISS Recommends Adamis Pharmaceuticals’ Stockholders Vote FOR Critical Proposals at Upcoming Annual Meeting
July 29, 2022 08:00 ET
|
Adamis Pharmaceuticals Corporation
ISS Recommends Stockholders Support Key Proposals Pertaining to a Reverse Stock Split and New Equity Incentive Plan The Deadline for Stockholders to Vote (or Change Their Vote) is 11:59 p.m. PT on...
Adamis Pharmaceuticals Issues Letter to Stockholders
July 21, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, July 21, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Appoints Vickie Reed to Board of Directors
May 26, 2022 16:05 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 26, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (Nasdaq: ADMP) today announced the appointment of Vickie Reed as a new director and member of the company’s board of...
Adamis Pharmaceuticals Announces Leadership Transition to Support New Phase of Innovation and Growth
May 18, 2022 17:00 ET
|
Adamis Pharmaceuticals Corporation
David J. Marguglio, Co-Founder and Chief Business Officer, Appointed President and CEO Dennis J. Carlo, Ph.D., Has Retired as Both CEO and Board Director SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE)...
Adamis Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 16:35 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 16, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Schedules First Quarter 2022 Financial Results Conference Call and Business Update
May 09, 2022 17:56 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 09, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Reports Full Year 2021 Financial Results and Provides Corporate Update
March 31, 2022 16:49 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
US WorldMeds and Adamis Pharmaceuticals Announce U.S. Launch of ZIMHI™ Naloxone Product
March 31, 2022 16:14 ET
|
Adamis Pharmaceuticals Corporation
LOUISVILLE, Ky. and SAN DIEGO, March 31, 2022 (GLOBE NEWSWIRE) -- USWM, LLC (US WorldMeds), and Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), today announced the U.S. launch and...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call and Business Update
March 24, 2022 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, March 24, 2022 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for allergy, opioid...
Adamis Pharmaceuticals Updates Comparative Pharmacology Model Data Supporting the Higher 5 mg Intramuscular Dose of Naloxone in ZIMHI™
December 01, 2021 07:30 ET
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that additional data in a quantitative systems pharmacology model supports the dose of...